Kancera AB (publ) has previously announced the Board's decision to execute the company's exclusive option to acquire the Fractalkine project from Acturum Real Estate AB after transfer of results and know-how. This transfer of results and know-how has now...
Read MoreBlocking the Fractalkine system has been shown in clinical trials to have the desired effects in humans against intractable forms of autoimmune diseases. The results are in line with the positive effects that Kancera has been able to demonstrate...
Read MoreTHE PERIOD JANUARY – DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income for the period amounted to SEK -22,3M (SEK -19.7M)...
Read MoreKancera AB (publ) presents new information on - how the company's Fractalkine blocker prevents immune cells (monocytes) to infiltrate the nerves and spinal cord, which prevents nerve damage and enhanced pain sensitivity associated with cancer treatment - the fact...
Read MoreThis is a translation from a swedish press release Stockholm dated 2016-12-23. Kancera AB (publ) today announced that Joachim Forsgren (MD, PhD) has been appointed Chief Medical Officer and will be medically responsible for Kancera product portfolio. He will...
Read MoreKancera AB (publ) today reported that the drug candidate KAN0440567 quickly and effectively counteracts the kind of pain that results from chemotherapy and that often prevents effective treatment of cancer. The results also indicate that the Kancera drug candidate...
Read MoreThe period January to September 2016 in brief R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m). Operating income for the period amounted to SEK -15.8m (SEK...
Read MoreIn connection with a presentation at the Swedish Shareholders' Association on 17 November in Vimmerby, Kancera communicates new results in the ROR project. These results indicate that the company's ROR inhibitors may work against a particular type of intractable...
Read MoreKancera AB (publ) announced today that Niclas Brynne has been appointed to lead Kancera's clinical development projects. He will be part of the management team and report directly to the CEO.
Read MoreAs a consequence of the acquisition of the subsidiary Kancera Förvaltning AB on 2016-06-16, the present Interim Report, Q2 2016, is prepared in accordance with IAS 34 and related parts of the Annual Accounts Act. The consolidated financial statements...
Read More